NDAINJECTIONINJECTABLEPriority Review
Approved
May 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
TENSILON (edrophonium chloride) by R-Pharm US. Approved for depression. First approved in 1951.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tensilon (edrophonium chloride) is an injectable acetylcholinesterase inhibitor approved in 1951 for the treatment of depression. The mechanism of action involves inhibition of acetylcholine breakdown, though clinical efficacy in depression remains poorly understood and this indication is now considered largely historical.
LOE Approaching
This product is in the final stages of its commercial lifecycle with minimal market presence, suggesting limited opportunities for brand expansion and a focus on legacy account management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on Tensilon offers minimal career growth due to its LOE status and historically limited market presence. Roles on this product are constrained to legacy account management and compliance rather than innovation or expansion initiatives.
Product Manager
Worked on TENSILON at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.